All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CEA (SCA431) h(28BBζ), which is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CEA antibody linked to a CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.
CAR Construction : SCA431 scFv-28ζ Fig.3 CD4 T cells were modified with the CAR and used for adoptive transfer in this study. CAR expression was monitored by flow cytometry using a phycoerythrin-labeled anti-mouse IgG1 antibody and an allophycocyanin-conjugated antibody directed against CD4. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.4 T cells with anti-CEA CAR (7.8 1021.0 105 cells/well) were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours. Interferon-gamma in the culture supernatant as marker for T-cell activation was determined by enzyme-linked immunosorbent assay (ELISA). Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.5 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study. Mouse CEA Panc02 pancreatic carcinoma cells and fibrosarcoma CEA C15A3 cells were used for comparison. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.6 CBLuc-marked Panc02 tumor cells and GLuc-marked T cells were recorded by bioluminescence imaging in the same mouse at the indicated days before and after T-cell transfer. Data of bioluminescence signals were quantified. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.7 Tissues from CEAtg mice treated with CAR-engineered or nonmodified T cells were stained with H&E and recorded for CEA by antibody staining. Wild-type (wt) mice treated with CAR T cells were analyzed for comparison. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.8 Lymphodepletion before therapy did not favor autoimmune colitis upon CAR T-cell infusion. Body weight of mice did not substantially alter during treatment. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : SCA431 scFv-28ζ Fig.9 Transduction efficiency of CARS into Teffs and Tregs. Expression of the CEA-specific CAR was detected by incubating the cells with soluble CEA followed by staining with an anti-CEA antibody. Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028. |
CAR Construction : SCA431 scFv-28ζ Fig.10 In vitro stimulation and cytotoxicity of CEA-specific CAR T cells. Colorectal tumors were extracted from CEABAC-2 mice and dissociated to serve as target cells for CD4+ CAR Teff stimulation. Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028. |
CAR Construction : SCA431 scFv-28ζ Fig.11 Cytotoxicity of CEA-specific CAR CD4+ Teffs, CD8+ Teffs, and Tregs towards CEA-expressing Capan-1 cells transfected with firefly luciferase, as measured by bioluminescence signal intensity. Control: Irrelevant CAR Teffs. Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy, 22(5), 1018-1028. |
CAR Construction : SCA431 scFv-28ζ Fig.1 Severe weight loss and the eventual death of CEA-Tg mice transferred with CEA-specific CAR-T cells. Cryostat sections of organs collected from mice at 17 day after tumor inoculation. Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
CAR Construction : SCA431 scFv-28ζ Fig.2 Increased efficacy of tumor growth suppression by CEA-specific CAR-T cells in preconditioned mice is associated with severe weight loss and eventual death of CEA-Tg mice, but not WT mice CAR-T cells prepared from CEA-Tg and WT mice and those mock-transduced T cells from WT mice were transferred into MC32a tumor-bearing CEA-Tg mice that also received fludarabine,cyclophosphamide, and total body irradiation. Body weight changes of CEA-Tg were analyzed at indicated time points. Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., ... & Shiku, H. (2016). Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology, 5(9), e1211218. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (SCA431) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX126). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION